Baseline characteristics of the population
| Baseline characteristics | Non-conization (n=187) | Conization (n=187) | P value |
| Age (years) (mean (SD)) | 48.11 (9.59) | 45.85 (10.22) | 0.91 |
| Body mass index (kg/m2) (mean (SD)) | 26.44 (6.18) | 25.05 (4.64) | 0.12 |
| Race (n (%)) | 0.36 | ||
| Caucasian | 155 (82.9) | 165 (88.2) | |
| Asian | 6 (3.2) | 8 (4.3) | |
| Latin American | 5 (2.7) | 2 (1.1) | |
| African | 2 (1.1) | 0 (0.0) | |
| Not reported | 19 (10.1) | 12 (6.4) | |
| Performance status (n (%)) | 0.12 | ||
| ECOG 0 | 166 (88.8) | 174 (93.0) | |
| ECOG 1 | 16 (8.6) | 6 (3.2) | |
| Not reported | 5 (2.6) | 7 (3.8) | |
| Approach (n (%)) | 0.76 | ||
| MIS | 90 (48.1) | 93 (49.7) | |
| Robotic | 6 (6.4) | 17 (18.7) | |
| Open | 97 (51.9) | 94 (50.3) | |
| Colpoprotective maneuvers (n (%)) | 35 (18.7) | 35 (18.7) | 1 |
| No use of uterine manipulator (n (%)) | 109 (67.7) | 123 (71.5) | 0.45 |
| Histotype (n (%)) | 0.83 | ||
| Squamous | 131 (70.1) | 131 (70.1) | |
| Adenocarcinoma | 49 (26.2) | 51 (27.3) | |
| Adenosquamous | 7 (3.7) | 5 (2.7) | |
| Tumor grade (n (%)) | 0.34 | ||
| G1 | 35 (18.7) | 42 (22.5) | |
| G2 | 96 (51.3) | 82 (43.9) | |
| G3 | 56 (29.9) | 63 (33.7) | |
| Largest tumor diameter (n (%)) | 0.12 | ||
| ≤2 cm | 119 (63.6) | 133 (71.1) | |
| >2 cm | 68 (36.4) | 54 (28.9) | |
| Depth of invasion (n (%)) | 0.78 | ||
| Superficial <1/3 | 69 (36.9) | 75 (40.1) | |
| Intermediate 1/3–2/3 | 80 (42.8) | 74 (39.6) | |
| Deep >2/3 | 38 (20.3) | 38 (20.3) | |
| Lymphovascular space invasion (n (%)) | 0.67 | ||
| No | 114 (61.0) | 110 (58.8) | |
| Yes | 73 (39.0) | 77 (41.2) | |
| Parametrial invasion (n (%)) | 0.32 | ||
| Negative | 183 (98.0) | 182 (97.3) | |
| Positive | 3 (1.5) | 1 (0.5) | |
| Not reported | 1 (0.5) | 4 (2.2) | |
| Margins status of radical hysterectomy specimen (n (%)) | 1 | ||
| Negative | 175 (93.6) | 175 (93.6) | |
| Positive or close ≤2 mm | 12 (6.4) | 12 (6.4) | |
| Nodal status (n (%)) | 0.46 | ||
| Negative | 173 (92.5) | 165 (90.4) | |
| Positive | 14 (7.5) | 18 (9.6) | |
| FIGO staging 2009 (n (%)) | 0.56 | ||
| IB1 ≤2 cm | 103 (55.1) | 94 (50.3) | |
| IB1 >2 cm | 65 (34.8) | 75 (40.1) | |
| IB2-II–III | 19 (10.2) | 18 (9.6) | |
| Adjuvant therapy (n (%)) | 0.91 | ||
| None | 107 (57.2) | 108 (57.8) | |
| Yes | 80 (42.8) | 79 (42.2) |
ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; MIS, minimally invasive surgery.